B7-33 is a novel peptide derived from the human relaxin-2 hormone, known for its potential benefits in reducing fibrosis, improving vascular function, and offering therapeutic effects for conditions such as acute heart failure and other cardiovascular diseases.
B7-33 is a synthetic single-chain peptide based on the human relaxin-2 hormone, designed for simplicity and effectiveness. Unlike the natural relaxin-2 peptide, which contains a complex structure with multiple elements (signal peptide, B chain, C chain, and COOH terminal), B7-33 features a streamlined design focusing solely on the B chain with an extended COOH terminal.
It specifically targets the RXFP1 receptor, which plays a critical role in its antifibrotic and pro-vascular effects. Slovakia Research highlights its potential to reduce fibrosis, control inflammation, and enhance vascular health. These properties make it a promising candidate for treating various conditions, including acute heart failure, pulmonary fibrosis, kidney diseases, and other cardiovascular or fibrotic disorders.
For example, in heart failure, it may reduce scar tissue that impairs the heart’s pumping ability. Similarly, in pulmonary fibrosis, it could help limit the build-up of fibrotic tissue, improving lung function. By addressing tissue damage and vascular issues, the peptide demonstrates significant potential for managing a range of severe and chronic diseases.
The B7-33 peptide differs from the endogenous relaxin-2 protein not only in structure but also in how it functions. Studies show that it primarily acts through the pERK signaling pathway, unlike relaxin-2, which mainly works via the cAMP pathway.
The pERK pathway plays a key role in regulating cell growth and survival, while the cAMP pathway is more involved in metabolism and energy regulation. Notably, relaxin-2’s antifibrotic effects through the cAMP pathway have been linked to potential tumor-promoting activity. In contrast, it may offer a safer therapeutic option.
It has a strong affinity for RXFP1 receptors, activating the pERK pathway and potentially increasing the production of matrix metalloproteinase 2 enzymes (MMP-2). MMP-2 is essential for breaking down extracellular matrix proteins, aiding in tissue repair and remodeling.
This activity could help reduce tissue scarring and fibrosis, a condition where excessive connective tissue hinders organ function. These unique properties make it a promising candidate for targeted antifibrotic therapy, emphasizing the need for further research into its potential applications.
Molecular Formula: C131H228N40O37S
Molecular Weight: 2987,75 g/mol
Sequence: VIKLSGRELVRAQIAISGMSTWSKRSL
View our B7-33 High-Performance Liquid Chromatography (HPLC) Certificate here.
Reduces Fibrosis: Research indicates that the peptide plays a crucial role in reducing the formation of fibrotic (scar-like) tissue by inhibiting the excessive production of collagen and other proteins that contribute to tissue stiffening. This makes it a promising candidate for treating conditions characterized by excessive fibrosis, such as those affecting the lungs, liver, or heart.
Recent Slovakia studies have specifically highlighted the therapeutic potential of inhaled B7, a B chain of recombinant human relaxin, for pulmonary fibrosis. In preclinical trials on mice with bleomycin-induced pulmonary fibrosis, B7 demonstrated significant benefits—reducing inflammation, collagen build-up, and key pathological markers. It also improved alveolar structure and suppressed the expression of genes and proteins associated with fibrosis [1]. These findings underscore the potential of inhaled B7 as a cost-effective, efficient treatment for pulmonary fibrosis, offering new hope for managing this challenging condition.
Lung Inflammation: The B7-33 nasal spray shows great potential for treating lung disease related conditions. It reduces inflammation in lung tissue, helping to ease symptoms of chronic conditions like COPD and asthma. It also helps manage pulmonary fibrosis by reducing scarring, making it valuable for treating progressive lung diseases. These benefits improve respiratory function and overall quality of life, offering hope for new treatments in pulmonary care.
Enhances Vascular Health: The peptide is a cost-effective derivative of the hormone Relaxin (RLX) that promotes vascular health, improves blood circulation, and reduces strain on the cardiovascular system. In a study on cardiomyopathy, the peptide demonstrated significant benefits, including reduced inflammation, fibrosis, and hypertrophy, alongside improved vascular function. Unlike the ACE inhibitor perindopril, which primarily reduced blood pressure and inflammation, it offers rapid anti-fibrotic effects, making it a promising option for managing heart conditions [2].
Cardioprotection: The peptide, derived from relaxin-2, demonstrates significant potential in protecting the heart, particularly in the treatment of acute heart failure and mitigating heart damage after ischemia-reperfusion injury. In a study on mice, it was shown to reduce infarct size, improve heart rate stability, and preserve cardiac function over 7 days. Additionally, in vitro studies revealed that it enhanced cardiomyocyte survival while reducing markers of endoplasmic reticulum stress via ERK1/2 signaling. These results suggest the peptide’s ability to offer acute cardioprotection and limit long-term myocardial damage [3].
Furthermore, the peptide may help prevent cardiac fibrosis, a condition that arises due to cardiac stress and contributes to heart failure. Fibrosis types, such as left ventricular (LV) fibrosis linked to hypertension or right ventricular (RV) fibrosis associated with pulmonary hypertension, highlight the importance of therapies targeting TGFβ and fibroblasts. These findings underscore the promise of relaxin proteins in addressing heart damage and supporting cardiac health [4].
Pre-eclampsia (PE): This hypertensive pregnancy disorder affecting 10% of pregnancies, may benefit from novel treatments like the relaxin peptide B7-33. Slovakia Studies in a rat model showed that B7-33 reduced blood pressure, inflammation markers (TNF-α, sFlt-1), and improved nitric oxide levels, restoring normal pregnancy parameters [5]. Another study found B7-33 and its lipidated version improved cytotrophoblast function by reducing anti-angiogenic factors and increasing vascular endothelial growth factor (VEGF expression), with the lipidated version offering a longer half-life. These findings highlight it’s potential as a therapeutic option for PE, with preclinical studies underway [6].
Coating for Transplant Material: In a preclinical study involving murine models, researchers tested a peptide-coated implant to evaluate its potential in reducing fibrosis. Over a six-week period, the controlled release of the peptide from the device coating led to a 49.2% decrease in fibrotic tissue accumulation, effectively minimizing implant thickness. These findings suggest that the peptide may play a role in limiting fibrotic responses, potentially improving the long-term performance of implanted medical devices [7].
Buy B7-33 Nasal Spray
Buy B7-33 nasal spray Slovakia for clinical research from Direct Sarms, available in 15ml and 30ml bottles. It is a non-invasive formulation for research into fibrosis and blood flow issues.
It offers fast absorption through the nasal cavity, bypassing the digestive system for improved effectiveness. By activating the RXFP1 receptor, it supports natural repair mechanisms, though further studies are needed to confirm safety and efficacy.
Buy B7-33 Peptide Vial
Buy B7-33 Peptide Vial Slovakia available as lyophilized powder in 2 mg and 6 mg vials for laboratory purposes. It requires bacteriostatic water to reconstitute the powder before use.
This high-quality formulation ensures stability and purity, enabling precise dosing for exploring RXFP1 receptor activation. Proper storage and handling are required for optimal use.
Is B7-33 safe to use?
It is currently intended for research purposes only and has not been approved for human consumption. Further studies and clinical trials are needed to establish its safety and long-term effects.
How should B7-33 be stored?
For optimal stability, it should be stored according to the manufacturer’s guidelines. Typically, the lyophilised powder needs to be kept in a cool, dry place, while solutions should be handled under sterile conditions and may require refrigeration.
Are there any side effects associated with B7-33?
As it is still under research and clinical evaluation, its full safety profile has not yet been established. Current studies have primarily focused on its potential benefits rather than adverse effects. Researchers caution that further investigations are necessary to identify any possible side effects or risks associated with its use.
Does B7-33 promote cancer progression?
As a selective relaxin receptor agonist, it offers potential in prostate cancer research due to its modified structure and targeted action. While relaxin is linked to tumour growth and invasiveness [8], B7-33 has shown anti-inflammatory and reparative effects in other contexts, suggesting it may not promote tumour progression. Further studies are needed to understand its impact on relaxin-linked pathways and its potential therapeutic role.
How does B7-33 differ from human relaxin-2?
B7-33 is a single-chain peptide, unlike the two-chain structure of human relaxin-2. This structural simplification makes B7-33 easier and less costly to produce. Additionally, B7-33 selectively activates specific signaling pathways, which may reduce potential side effects associated with broader activation by relaxin-2.
For more information, explore our latest blog posts dedicated to B7-33 peptides.
Buy B7-33 peptide from Direct Sarms, a trusted provider of research-grade peptides. It’s available in 2 mg and 6 mg lyophilized powder vials, 15 ml and 30 ml nasal sprays, and 2 mg pre-mixed pens. Made to the highest purity and quality standards, this peptide is ideal for laboratory use, ensuring reliable results for your research.
At Direct Sarms, we ensure rigorous quality control to preserve the potency and reliability of our peptides. Our focus on precision and consistency guarantees accurate dosing and dependable results for all your research needs.
[1] Yuhua Liu, Shaofang Wang, Xueqi Gong, Yingshuo Wang, and Tonghui Xu (2021) Inhaled B7 alleviates bleomycin-induced pulmonary fibrosis in mice – Bioorganic & Medicinal Chemistry, Volume 50, 15 November 2021, Page 116482.
[2] Fariha Alam, Tracey A Gaspari, Barbara K Kemp-Harper, Edward Low, Aaron Aw, et al (2023) The single-chain relaxin mimetic, B7-33, maintains the cardioprotective effects of relaxin and more rapidly reduces left ventricular fibrosis compared to perindopril in an experimental model of cardiomyopathy – Biomedicine & Pharmacotherapy, 2023 Apr, Volume 160, Page 114370.
[3] Teja Devarakonda, Adolfo G Mauro, Geronimo Guzman, Sahak Hovsepian, et al (2020) B7‐33, a Functionally Selective Relaxin Receptor 1 Agonist, Attenuates Myocardial Infarction–Related Adverse Cardiac Remodeling in Mice – Journal of the American Heart Association, 2020 Apr 16, Volume 9 (Issue 8), Page e015748.
[4] Katharina Schimmel, Kenzo Ichimura, Sushma Reddy, Francois Haddad, and Edda Spiekerkoetter (2022) Cardiac Fibrosis in the Pressure Overloaded Left and Right Ventricle as a Therapeutic Target – Frontiers in Cardiovascular Medicine, 2022 May 6, Volume 9, Page 886553.
[5] Ahmed F Pantho, Bs, Lorena Amaral, PhD, Nathan Campbell, BS, Syeda Afroze, PhD, et al (2024) Abstract 16: A Novel H2 Relaxin B-Chain-Only Peptide Variant B7-33 Improves The Pathophysiology Of Placental Ischemia In The Reduced Uterine Perfusion Pressure Rat Model Of Preeclampsia – AHA/ASA Journals, Hypertension, Volume 81, Number Supplement 1, 14 October 2024.
[6] Syeda H Afroze, Ahmed F Pantho, David C Sprague, Thomas J Kuehl, et al (2019) Abstract P3042: Novel Peptide B7-33 and It’s Lipidated Derivative Protect Cytotrophoblasts From Preeclampsia Phenotype in a Cellular Model of the Syndrome – AHA/ASA Journals, Hypertension, Volume 74, Number Suppl_1, 4 September 2019.
[7] Nicholas G Welch, Shayanti Mukherjee, Mohammed A Hossain, Praveen Praveen, et al (2019) Coatings Releasing the Relaxin Peptide Analogue B7-33 Reduce Fibrotic Encapsulation – ACS Appl Materials & Interfaces, 2019 Dec 11, Volume 11 (Issue 49), Pages 45511-45519.
[8] Shu Feng, Irina U Agoulnik, Natalia V Bogatcheva, Aparna A Kamat, et al (2007) Relaxin promotes prostate cancer progression – Clinical Cancer Research, 2007 Mar 15, Volume 13 (Issue 6), Pages 1695-702.
ALL CONTENT AND PRODUCT INFORMATION AVAILABLE ON THIS WEBSITE IS FOR EDUCATIONAL PURPOSES ONLY.
DISCLAIMER: These products are intended solely as a research chemical only. This classification allows for their use only for research development and laboratory studies. The information available on our Direct Sarms website is provided for educational purposes only. These products are not for human or animal use or consumption in any manner. Handling of these products should be limited to suitably qualified professionals. They are not to be classified as a drug, food, cosmetic, or medicinal product and must not be mislabelled or used as such.
Worldwide shipping
Visa/Mastercard/Zelle
Cryptocurrency /Transfers
Safe and Secure Shopping
We Distribute From
YOU MUST BE OVER 21 YEARS IN ORDER TO USE THIS WEBSITE. All of the products are to be handled only by properly trained and qualified LABORATORY or RESEARCH professionals.
